Pancreatic enzyme replacement therapy for pancreatic exocrine insufficiency in the 21st century

Figure 7 Randomized cross-over study in patients with cystic fibrosis and pancreatic insufficiency that compared plain uncoated enzymes (Pancrex V Forte n = 14) and 3 different enteric coated preparations [EC1:Pancreatin Merk, EC2: Creon and EC3: Pancrease (n = 19)] using the same lipase dosage. The median and range are shown of fecal fat absorption. With the numbers above the columns ( ) indicating the percent of patients with > 90% fat absorption. None reliably resulted in normalization of fat malabsorption[42].